intensive care patients with suspected or proven fungal infection, who undergo hemofiltration MedDRA version: 9.1 Level: LLT Classification code 10042941 Term: Systemic fungal infection NOS
Conditions
Interventions
Trade Name: Ecalta
Pharmaceutical Form: Powder for solution for infusion
CAS Number: 166663258
Other descriptive name: ANIDULAFUNGIN
Concentration unit: mg milligram(s)
Concentration type: up to
Conce
Sponsors
MUW, Universitätsklinik für Innere Medizin I, Abteilung für Infektionskrankheiten und Tropenmedizin
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: a) Age 19 to 70 years b) Suspected or proven infection requiring parenteral antifungal therapy. c) Continuous venovenous hemofiltration because of an acute renal failure. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: a) Known history of hypersensitivity to echinocandins. b) An expected survival of less than three days. c) Known alcohol dependency, epilepsy, pregnancy or liver failure. d) Neutropenic patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The study is conducted to investigate the pharmacokinetics of anidulafungin during CVVHDF in critically ill patients.;Secondary Objective: ;Primary end point(s): Pharmacokinetic Data in patients with renal insufficiency and hemofiltration | — |
Countries
Austria
Outcome results
None listed